MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 480.66% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 81.39M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 81.39M.
Undervalued
The company’s latest PE is -9.38, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 53.71M shares, decreasing 3.14% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 14.83K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.15.